| Physiologic indirect response models characterize diverse types of pharmacodynamic effects WJ Jusko, HC Ko Clinical Pharmacology & Therapeutics 56 (4), 406-419, 1994 | 401 | 1994 |
| A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia MH Kollef, J Chastre, M Clavel, MI Restrepo, B Michiels, K Kaniga, I Cirillo, ... Critical Care 16, 1-17, 2012 | 239 | 2012 |
| Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin NC Kaarsholm, HC Ko, MF Dunn Biochemistry 28 (10), 4427-4435, 1989 | 207 | 1989 |
| Convergence of direct and indirect pharmacodynamic response models WJ Jusko, HC Ko, WF Ebling Journal of pharmacokinetics and biopharmaceutics 23, 5-8, 1995 | 73 | 1995 |
| Model‐based clinical drug development in the past, present and future: a commentary H Kimko, J Pinheiro British journal of clinical pharmacology 79 (1), 108-116, 2015 | 64 | 2015 |
| Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development A Bernard, H Kimko, D Mital, I Poggesi Expert opinion on drug metabolism & toxicology 8 (9), 1057-1069, 2012 | 49 | 2012 |
| A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection BS Adiwijaya, TL Kieffer, J Henshaw, K Eisenhauer, H Kimko, JJ Alam, ... PLoS computational biology 8 (1), e1002339, 2012 | 42 | 2012 |
| Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models XS Xu, A Dunne, H Kimko, P Nandy, A Vermeulen Journal of pharmacokinetics and pharmacodynamics 38, 423-432, 2011 | 38 | 2011 |
| Toward dynamic prescribing information: codevelopment of companion model‐informed precision dosing tools in drug development TM Polasek, CR Rayner, RW Peck, A Rowland, H Kimko, ... Clinical pharmacology in drug development 8 (4), 418-425, 2019 | 36 | 2019 |
| Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis H Kimko, E Gibiansky, L Gibiansky, HL Starr, J Berwaerts, J Massarella, ... Journal of pharmacokinetics and pharmacodynamics 39, 161-176, 2012 | 36 | 2012 |
| What does it take to make model-informed precision dosing common practice? Report from the 1st Asian symposium on precision dosing TM Polasek, A Rostami-Hodjegan, DS Yim, M Jamei, H Lee, H Kimko, ... The AAPS journal 21, 1-9, 2019 | 35 | 2019 |
| Clinical trial simulations: applications and trends HHC Kimko, CC Peck Springer Science & Business Media, 2010 | 35 | 2010 |
| Pharmacokinetic–pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach FJ Flores-Murrieta, HC Ko, DM Flores-Acevedo, FJ López-Muñoz, ... Journal of pharmacokinetics and biopharmaceutics 26, 547-557, 1998 | 29 | 1998 |
| A spatial quantitative systems pharmacology platform spQSP-IO for simulations of Tumor–Immune interactions and effects of checkpoint inhibitor immunotherapy C Gong, A Ruiz-Martinez, H Kimko, AS Popel Cancers 13 (15), 3751, 2021 | 23 | 2021 |
| Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model A Ruiz-Martinez, C Gong, H Wang, RJ Sové, H Mi, H Kimko, AS Popel PLoS computational biology 18 (7), e1010254, 2022 | 22 | 2022 |
| Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections H Kimko, X Xu, P Nandy, MN Samtani, RS Strauss, P Bagchi, GJ Noel Antimicrobial agents and chemotherapy 53 (8), 3371-3374, 2009 | 20 | 2009 |
| Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections H Kimko, B Murthy, X Xu, P Nandy, R Strauss, GJ Noel Antimicrobial agents and chemotherapy 53 (3), 1228-1230, 2009 | 18 | 2009 |
| Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial JE Le Lay, Q Du, MB Mehta, N Bhagroo, BT Hummer, J Falloon, ... Science Translational Medicine 13 (590), eabb0602, 2021 | 17 | 2021 |
| Pharmacodynamic Modeling of Finasteride, a 5α‐Reductase Inhibitor HC Ko, WJ Jusko Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 15 (4 …, 1995 | 16 | 1995 |
| Systems pharmacology and pharmacodynamics DE Mager, HHC Kimko Springer, 2016 | 15 | 2016 |
